Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
General Discussion
Showing Original Post only (View all)"Lambda variant shows vaccine resistance in lab" [View all]
Link to tweet
Tweet text:
Olivia Messer 🌊
@OliviaMesser
Lambda variant shows vaccine resistance in lab is one of the more terrifying phrases Ive ever read. Goodness, sometimes the tragedy of how preventable this moment was is overwhelming.
People queue to receive a dose of the Pfizer BioNTech vaccine at the Central Middlesex Hospital in London, Britain, August 1, 2021. REUTERS/Henry Nicholls
Delta infections among vaccinated likely contagious; Lambda variant shows vaccine resistance in lab
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19.
reuters.com
5:56 AM · Aug 3, 2021
Olivia Messer 🌊
@OliviaMesser
Lambda variant shows vaccine resistance in lab is one of the more terrifying phrases Ive ever read. Goodness, sometimes the tragedy of how preventable this moment was is overwhelming.
People queue to receive a dose of the Pfizer BioNTech vaccine at the Central Middlesex Hospital in London, Britain, August 1, 2021. REUTERS/Henry Nicholls
Delta infections among vaccinated likely contagious; Lambda variant shows vaccine resistance in lab
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19.
reuters.com
5:56 AM · Aug 3, 2021
https://www.reuters.com/business/healthcare-pharmaceuticals/delta-infections-among-vaccinated-likely-contagious-lambda-variant-shows-vaccine-2021-08-02/
*snip*
Lambda variant shows vaccine resistance
The Lambda variant of the coronavirus, first identified in Peru and now spreading in South America, is highly infectious and more resistant to vaccines than the original version of the virus the emerged from Wuhan, China, Japanese researchers have found. In laboratory experiments, they found that three mutations in Lambda's spike protein, known as RSYLTPGD246-253N, 260 L452Q and F490S, help it resist neutralization by vaccine-induced antibodies. Two additional mutations, T76I and L452Q, help make Lambda highly infectious, they found. In a paper posted on Wednesday on bioRxiv ahead of peer review, the researchers warn that with Lambda being labeled a "Variant of Interest" by the World Health Organization, rather than a "Variant of Concern," people might not realize it is a serious ongoing threat. Although it is not clear yet whether this variant is more dangerous than the Delta now threatening populations in many countries, senior researcher Kei Sato of the University of Tokyo believes "Lambda can be a potential threat to the human society."
Third mRNA dose may boost antibody quantity, but not quality
Among fully vaccinated people who never had COVID-19, getting a third dose of an mRNA vaccine from Pfizer (PFE.N)/BioNTech or Moderna (MRNA.O) would likely increase levels of antibodies, but not antibodies that are better able to neutralize new virus variants, Rockefeller University researchers reported on Thursday on bioRxiv ahead of peer review. They note that in COVID-19 survivors, the immune system's antibodies evolve during the first year, becoming more potent and better able to resist new variants. In 32 volunteers who never had COVID-19, they found that antibodies induced by mRNA vaccines did evolve between the first and second shots. But five months later, vaccine-induced antibodies were "equivalent" to those seen after the second dose, with "little measurable improvement" in the antibodies' ability to neutralize a broad variety of new variants, said coauthor Michel Nussenzweig. Therefore, he said, giving those individuals a third dose of the same vaccine would likely result in higher levels of antibodies that remain less effective against variants. "At the moment, the vaccine remains protective against serious infection," Nussenzweig said. "Should we learn that efficacy is indeed waning for serious infection, which is not really the case to date," then a booster dose of "whatever is available" might become appropriate, he added. Should an updated vaccine become available that protects against specific variants, "then that would be the choice."
*snip*
20 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies